# LongeVC

> LongeVC is a VC fund in Lugano backing Health Care and Biotechnology. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lugano, Switzerland
- Total investments: 22
- Last investment: Oct 2025
- Lead investor: 23%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/longevc
- X (Twitter): https://twitter.com/hqlongevc?lang=en
- Website: http://www.longevc.com/

LongeVC is a VC fund in Lugano focused on Health Care and Biotechnology. LongeVC was created to support early-stage biotech and longevity-focused founders on their way to gain industrial momentum, raise capital, and grow to become the shapers of tomorrow's biotech industry.

## Contacts

5 contacts available for LongeVC. Shizune tracks 3 team members at LongeVC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/longevc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.3M–$12M |
| Series A | $17M–$94M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 59% |
| Biotechnology | 13 | 59% |
| Therapeutics | 6 | 27% |
| Artificial Intelligence | 4 | 18% |
| Life Science | 3 | 14% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 45% |
| Series A | 7 | 32% |
| Venture - Series Unknown | 3 | 14% |
| Pre-Seed | 1 | 5% |
| Funding Round | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 11 | 50% |
| United Kingdom | 4 | 18% |
| Canada | 1 | 5% |
| Estonia | 1 | 5% |
| Hong Kong | 1 | 5% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Garri Zmudze | Co-Founding Partner & Managing Partner | 8 | https://shizune.co/investors/profile/garri-zmudze |
| Ilya Suharenko | Managing Partner and Co-Founder | 1 | https://shizune.co/investors/profile/ilya-suharenko |
| Sergey Jakimov | Co-Founder and Managing Partner | 3 | https://shizune.co/investors/profile/sergey-jakimov |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Valink Therapeutics | Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M | Seed | Oct 20, 2025 |  |
| Trogenix | Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M | Series A | Oct 06, 2025 |  |
| Constructive Bio | Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. |  | Venture - Series Unknown | Apr 03, 2025 |  |
| SiPhox Health | SiPhox offers a handheld testing device with RNA/DNA and protein testing for point-of-care and At-Home solutions. The company's kit is made by multiplexing RNA, antibody, and antigen tests on a single silicon photonic chip which is amplified by plasmon resonance and silicon photonic resonator readout, enabling users to undertake tests fordisease safely and in a disposable point-of-care and at-home manner.SiPhox was founded in 2020 and is based in Cambridge, Massachusetts, USA. |  | Series A | Mar 04, 2025 |  |
| Proton Intelligence | Proton Intelligence provides biomarker monitoring to manage chronic disease and save lives. The first biomarker is potassium, targeting hyperkalemia in chronic kidney disease (CKD) patients who have additional co-morbidities ProtonIntel was founded in 2020 and was headquartered in Vancouver, Canada. | $7M | Seed | Dec 24, 2024 |  |
| Glyphic Biotechnologies | We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biologyand disease. |  | Seed | Nov 25, 2024 |  |
| Melio | Melio provides a quick and comprehensive blood test that detects all prevalent infections. Their technology allows for prompt and targeted therapy while also combating antibiotic resistance. Melio is headquartered in Santa Clara, California. | $4M | Seed | Jun 30, 2024 |  |
| Catena Biosciences | Catena Biosciences is a biotechnology company that offers protein conjugation, building biologic structures, and medical research. | $2.4M | Seed | May 10, 2024 |  |
| Rubedo Life Sciences | Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M | Series A | Apr 22, 2024 |  |
| Niksen Lab | Ani Biome is a longevity biotech startup that has the mission of optimizing and enhancing one's mind |  | Seed | Mar 03, 2024 |  |

10 of 22 investments shown.

## Co-investors
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 4 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 3 deals together
- [Adaptive Capital Partners](https://shizune.co/investors/profile/adaptive-capital-partners) — VC Fund, 2 deals together
- [Cancer Fund](https://shizune.co/investors/profile/cancer-fund) — VC Fund, 2 deals together
- [FemHealth Ventures](https://shizune.co/investors/profile/femhealth-ventures) — VC Fund, 2 deals together
- [Formic Ventures](https://shizune.co/investors/profile/formic-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Specialist VC](https://shizune.co/investors/profile/united-angels-vc) — VC Fund
- [Superangel](https://shizune.co/investors/profile/superangel) — VC Fund
- [Tera Ventures](https://shizune.co/investors/profile/tera-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Hong Kong](https://shizune.co/investors/biotechnology-investors-hong-kong)
- [Biotechnology VC Funds in Hong Kong](https://shizune.co/investors/biotechnology-vc-funds-hong-kong)
- [Biotech VC Funds in Hong Kong](https://shizune.co/investors/biotech-vc-funds-hong-kong)
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)
- [Consumer Investors in Estonia](https://shizune.co/investors/consumer-investors-estonia)
- [Consumer VC Funds in Estonia](https://shizune.co/investors/consumer-vc-funds-estonia)

## FAQ

### What does LongeVC invest in?

LongeVC invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is LongeVC's check size?

LongeVC typically joins rounds of $1.3M–$12M at Seed and $17M–$94M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LongeVC participates in.

### How do I contact LongeVC?

Public channels for LongeVC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LongeVC?

The team at LongeVC includes Garri Zmudze (Co-Founding Partner & Managing Partner), Ilya Suharenko (Managing Partner and Co-Founder) and Sergey Jakimov (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co